Hansa Biopharma
Sweden - LundPharmaceutical
Focus: Hansa Biopharma is a Swedish public biotech specializing in novel immunomodulatory enzymes targeting transplantation and acute autoimmune diseases. The company maintains a focused pipeline with two lead candidates (Imlifidase and IdeS) in mid-to-late stage development.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
4
Should You Work at Hansa Biopharma?
AI assessmentHansa is a focused immunology-stage biotech with meaningful clinical progress but minimal hiring velocity and pre-revenue status—best suited for scientists and clinicians seeking deep pipeline ownership in a niche therapeutic area.
Why Work Here
- Lead program Imlifidase has reached Phase 3 in two indications (kidney transplantation in highly sensitized patients and anti-glomerular basement membrane antibody disease), providing near-term regulatory visibility.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Imlifidase administered in the ConfIdeS study
Kidney Transplantation in Highly Sensitized PatientsClinical Trials (1)
NCT05714514Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
N/AHelp build intelligence for Hansa Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.